- Home
- AFRI vs DERM Comparison
AFRI vs DERM Comparison
Compare AFRI & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRI | DERM |
|---|---|---|
| Founded | 1943 | 2014 |
| Country | Gibraltar | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.1M | 213.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AFRI | DERM |
|---|---|---|
| Price | $11.03 | $7.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 23.8K | ★ 143.4K |
| Earning Date | 12-15-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $201,916,000.00 | $59,399,000.00 |
| Revenue This Year | N/A | $18.34 |
| Revenue Next Year | N/A | $54.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.82 |
| 52 Week Low | $7.47 | $3.54 |
| 52 Week High | $11.42 | $9.40 |
Technical Indicators
Market Signals| Indicator | AFRI | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 39.88 |
| Support Level | $10.45 | $7.70 |
| Resistance Level | $11.42 | $8.11 |
| Average True Range (ATR) | 0.50 | 0.33 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 53.47 | 5.29 |
Price Performance
Historical ComparisonAbout AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.